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Evaluation of intravenous voriconazole in patients
with compromised renal function
Craig M Lilly1, Verna L Welch2, Thomas Mayer1, Paul Ranauro1, Joanne Meisner1 and David R Luke2*
Abstract
Background: Incorporation of the solubilizing excipient, sulfobutylether-β-cyclodextrin (SBECD), in the intravenous
(IV) formulation of voriconazole has resulted in the recommendation that this formulation be used with caution in
patients with creatinine clearances (Clcr) < 50 mL/min. This study evaluated the safety of IV voriconazole compared
with two other IV antifungals not containing SBECD in patients with compromised renal function.
Methods: A total of 128 patients aged 11–93 years who had a baseline Clcr < 50 mL/min between January 1, 2007
and December 31, 2010 were identified from a database of a university-affiliated inpatient healthcare system; of
these, 55 patients received caspofungin, 54 patients received fluconazole, and 19 patients received voriconazole.
Changes in serum creatinine (Scr) and Clcr levels while on therapy were compared with baseline values and
between groups.
Results: The groups had similar characteristics apart from the larger proportion of females that received
fluconazole. Baseline Scr was higher in those receiving caspofungin, but maximal increases of Scr and decreases in
Clcr were greatest for the fluconazole group. Acute kidney injury (AKI), assessed by RIFLE criteria, was more frequent
in the fluconazole vs. the caspofungin group (p < 0.01); incidence of AKI in the voriconazole group was not
significantly different than found in the other two groups. The infecting organism was a predictor of AKI and
formulation with SBECD was not.
Conclusions: Treatment of fungal infections in patients with compromised renal function with an
SBECD-containing antifungal agent was not associated with AKI in clinical practice. Since the infecting organism
was associated with AKI, decision on which antifungal to use should be determined by susceptibilities to the
organism and not the incorporation of SBECD in the IV formulation.
Keywords: Voriconazole, Caspofungin, Fluconazole, Renal dysfunction, Sulfobutylether-β-cyclodextrin, SBECD,
Acute kidney injury
Background
The incidence of serious fungal infections has increased
over the last two decades [1], coincident with increased
prevalence of immunocompromised patients, including
those treated for cancer, acquired immune deficiency
syndrome (AIDS), and those treated with immunosup-
pressants in the setting of organ transplantation and
autoimmune disease. Historically, yeasts were the most
prevalent cause of fungal infections with Candida
albicans being the most frequently identified. More
recently, yeast infections have declined following the
introduction and wide spread use of fluconazole and
lipid-based amphotericin-B formulations. Further,
there has been a shift in the frequency of isolates from
C. albicans to non-albicans species, most notably C.
glabrata and C. parapsilosis [2,3]. This decline in
Candidal infections was associated with a rise in mould
infections including aspergillosis [4]. More recently,
the incidence of Aspergillus infections has been stable,
[5,6]. However, a rising incidence of nosocomial infec-
tions by other filamentous fungi has been observed.
These previously ultra-rare fungal diseases, such as
Scedosporium spp., Fusarium spp., and Zygomycetes
spp., are becoming more prevalent, particularly in
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immunocompromised patients in tertiary care cancer
centers [7,8].
The increase in the availability of agents that are avail-
able to treat fungal infections allows individual agents
to be selected based on the sensitivity of the organism
and the potential toxicity profile of the antifungal agent.
The high incidence of renal failure associated with
the administration of polyenes has led to sensitivity
regarding adverse renal effects of antifungal agents.
Nephrotoxicity associated with the administration of
first generation β-cyclodextrins [9] led to warnings
and restrictions that have made it difficult to study the
nephrotoxicity of later generation cyclodextrins. SBECD is
a second-generation cyclodextrin chemically-engineered
not to accumulate in renal epithelial cells and thus avoid
acute kidney injury. Despite limited evidence that SBECD
has not been associated with renal impairment [10,11],
restrictions in its use in patients with estimated creatinine
clearances (Clcr) less than or equal to 50 mL/min have
been documented [12].
Our study is designed to test the hypothesis that treat-
ment of a known or suspected fungal infection that is
serious enough to warrant the use of an intravenous
agent in patients with impaired renal function at the
start of therapy with an SBECD-containing antifungal is
associated with a higher frequency of renal dysfunction
than treatment with a non-SBECD containing anti-
fungal. To date, there have been no comprehensive eva-
luations incorporating large population sizes of clinical
populations in the literature. We found in our study that
the inclusion of SBECD was not associated with
drug-associated kidney injury in acutely-ill patients with
systemic fungal infections.
Results
A total of 128 patients with baseline Clcr < 50 mL/min and
meeting all inclusion and exclusion criteria were analyzed
from the aforementioned database. Fifty-five patients
received caspofungin, 54 patients received fluconazole,
and 19 patients received IV voriconazole. The groups were
well matched with regard to age, race, comorbidities, and
the concomitant administration of a known nephrotoxic
agent (Table 1). There were significantly more women in
the fluconazole group and this difference could not be
attributed to treatment of a mucosal infection. Further, a
disproportionate number of patients with diagnosed as-
pergillosis were treated with voriconazole. Approximately
three-quarters of the voriconazole patients were treated
with a concomitant nephrotoxic agent, as compared with
56% and 50% of those treated with caspofungin and fluco-
nazole, respectively. A total of 21 (16%) patients received
multiple concomitant nephrotoxic agents: 5 (26%) vorico-
nazole patients (all receiving 2 concomitant nephrotoxic
agents); 10 (18%) caspofungin patients (70%, 10%, and
20% receiving 2, 3, and 4 nephrotoxic agents, respectively);
and 6 (11%) fluconazole patients (50% of patients each re-
ceiving 2 or 3 concomitant nephrotoxic agents).
The underlying conditions are also listed in Table 1.
More than half of the patients were being treated in the
intensive care unit. Seventy-five percent of all patients
had presumed or confirmed fungal disease, as deter-
mined by an Infectious Diseases consultant (9 [47%], 46
[84%], and 42 [78%] patients administered voriconazole,
caspofungin, and fluconazole, respectively, NS; Table 1).
Baseline renal functional indices are listed in Table 2.
Significant differences in baseline Scr and blood urea
nitrogen (BUN) levels by treatment group were present;
the caspofungin group had higher levels than both of
the other treatment groups. However, the differences in
baseline estimated Clcr values were not significant
among the groups. Clcr values, as calculated by the
Cockcroft-Gault method or the MDRD equation, were
not significantly different; hence, all comparisons were
made using the Cockcroft-Gault method.
The changes in renal function as a function of time and
antifungal agent or formulations containing SBECD and
not containing SBECD are presented in Figures 1A and 1B,
respectively. Non-SBECD containing agents had signifi-
cantly lower nadir Clcr values than those observed with the
SBECD containing antifungal, as reflected by change in the
RIFLE criteria as well as absolute values (Table 3). Similarly,
there were significant differences of maximal increase from
baseline Scr levels among the groups with the non-SBECD
containing agents having greater increases than the SBECD
containing agent. There were no significant differences
among the groups in the incidence of renal dysfunction at
the time of antifungal agent completion of therapy, as
stratified by baseline renal function of Clcr < 30 mL/min or
Clcr 30 – 50 mL/min (EOT; Table 3).
The differences in 28-day mortality among the three
treatment groups were not statistically significant.
Mortality of patients in the voriconazole, caspofungin,
and fluconazole treatment groups was 42.1%, 29.1%, and
25.9% respectively (p = 0.44).
Stepwise logistic regression analyses were performed
using the following 7 independent variables: age, race,
comorbidities, concomitant treatment with a nephrotoxic
agent, the presence or absence of SBECD, and site of in-
fection which was recoded into 3 groups (abdominal +
lung, systemic, and urine + wound). The coefficient for
infecting organism had a Wald statistic equal to 3.90 and
a p-value of 0.048. Thus, this model identified the infect-
ing organism as the only significant predictor of renal dys-
function by the RIFLE criteria.
Discussion
This study found no evidence of renal toxicity that was
attributable to the solubilizing agent, sulfobutylether-β-
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cyclodextrin (SBECD), in patients with impaired renal
function (Clcr < 50 mL/min) who were treated with an
intravenous antifungal agent in clinical practice. The max-
imal increase in Scr levels was less and calculated nadir
Clcr was higher for the SBECD-containing voriconazole
group than those of fluconazole and caspofungin groups
that did not contain SBECD. Importantly, SBECD was not
associated with increased renal dysfunction during or at
the end of therapy.
Voriconazole, a second-generation triazole, is a steric
inhibitor of fungal cytochrome P450-dependent 14α-sterol
demethylase, which is essential for the conversion of lanos-
terol to ergosterol required for building the cell mem-
branes of fungal organisms [13]. Like other triazoles,
voriconazole has activity for this enzyme for both yeast and
moulds, whereas fluconazole, the backbone structure of
voriconazole, is only active against yeast. The early devel-
opment plan for voriconazole incorporated the medical
need for an intravenous formulation [written communica-
tion, Chris Hitchcock, PhD, Pfizer Inc]. Since voriconazole
has a low aqueous solubility (0.7 mg/mL) [14], its intraven-
ous formulation includes SBECD as a solubilizing agent.
Table 2 Renal function at the start of therapy
Parameter Voriconazole Caspofungin Fluconazole p-value for
overall
difference
Baseline
Scr
(mg/dL)
2.1 (0.9) 2.8 (1.5) 2.2 (1.3) 0.04
Baseline
BUN
(mg/dL)
33.3 (31.9) 56.5 (39.8) 48.7 (28.7) 0.04
Baseline
Clcr
(mL/min)
Cockcroft-
Gault
method
33.9 (9.0) 28.2 (12.0) 30.4 (10.3) 0.14
MDRD1
calculation
33.3 (14.0) 28.4 (17.1) 32.1 (15.5) 0.36
1Modification of Diet in Renal Disease.
Table 1 Patient characteristics
Parameter Voriconazole Caspofungin Fluconazole p-value
for
overall
difference
n (%) 19 (14.8) 55 (43.0) 54 (42.2)
Age, Mean (SD) 61.7 (13.9) 63.9 (13.9) 63.7 (14.7) 0.83
Male, n (%) 10 (52.6) 34 (61.8) 20 (37.0) 0.03
White, n (%) 17 (89.5) 43 (78.2) 49 (90.7) 0.63
Length of treatment (days)
Mean (SD) 8.1 (6.3) 8.6 (5.3) 9.8 (9.8) 0.62
Median (IQR) 6.0 (4–12) 7.0 (5–11) 8.0 (5–11) 0.53
Min, Max 2, 29 2, 27 2, 74 NS
Comorbidities: Diabetes mellitus, hypertension or nephropathy, n (%) 11 (57.9) 46 (83.6) 43 (79.6) 0.06
Underlying condition, n (%) 0.001
Cancer 12 (63)* 7 (13) 13 (24)
HIV 0 0 1
ICU 15 (79) 31 (56) 26 (48)
Immunosuppression** 12 (63) 3 (5) 12 (22)
More than 1 underlying condition 12 (63) 9 (16) 16 (30)
Concomitant nephrotoxic agent, n (%) 14 (73.7) 31 (56.4) 27 (50.0) 0.20
Underlying fungal disease, n (%)* 0.002
Candida spp. 5 (55.6) 43 (93.5) 39 (92.9)
Aspergillus spp. 4 (44.4) 3 (6.5) 3 (7.1)
Indication for antifungal therapy, n (%) † NS
Prophylaxis 10 (53) 8 (15) 5 (9)
Empiric 0 1 (2) 5 (9)
Presumed or Confirmed 9 (47) 46 (84) 42 (78)
*10 patients with AML were treated with voriconazole prophylaxis.
**Chemotherapy, transplant rejection prevention or treatment, ≥ 1 mg/kg prednisone.
†Cases were included only when an Infectious Diseases consultant determined that the isolate represented an infection rather than colonization.
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Figure 1 A: Kaplan-Meier plot of patients who meet the RIFLE criteria by treatment with intravenous voriconazole (____),
caspofungin (_ _ _ _), and fluconazole (. . . . .). B: Kaplan-Meier plot of patients who meet the RIFLE criteria by formulations containing SBECD
(____) and those with formulations which do not contain SBECD (_ _ _ _).
Table 3 Differences in renal function during therapy
Parameter Voriconazole Caspofungin Fluconazole
Baseline Clcr (mL/min) <30 30–50 p-value <30 30–50 p-value <30 30–50 p-value
n (%) 6 (31.6) 13 (68.4) – 33 (60.0) 22 (40.0) – 27 (50.0) 27 (50.0) –
Maximum ↑ Scr, mg/dL (SD) 0.68 (1.01) 0.62 (0.54) 0.88 1.17 (1.9) 0.15 (0.78) 0.02 2.6 (2.7) 2.0 (2.0) 0.33
Lowest Clcr during treatment, mL/min (SD) 16.8 (3.7) 31.7 (7.3) 0.0002 15.8 (6.0) 34.6 (7.7) <0.0001 13.9 (5.1) 24.3(8.2) <0.0001
Clcr at EOT, mL/min (SD) 28.7 (18.1) 50.3(27.8) 0.11 46.4(43.1) 59.5(28.4) 0.21 30.6(19.2) 49.0(22.6) 0.0025
% Change Clcr (Lowest-SOT)/SOT (SD) −24.6 (12.6) −19.6 (13.4) 0.45 −19.4(17.7) −15.6(15.1) 0.41 −35.3(18.4) −37.5(20.7) 0.68
Renal dysfunction, n (%) 3 (50.0) 4 (30.8) 0.42 12 (36.4) 3 (13.6) 0.06 17 (63.0) 15 (55.6) 0.58
Scr: serum creatinine; Clcr: creatinine clearance; EOT: end of therapy, SOT: start of therapy.
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Naturally occurring cyclodextrins, notably α- and β-
cyclodextrins, are reabsorbed and concentrated in the
renal tubule, resulting in acute kidney injury at clinically-
translatable doses in animal models [9]. SBECD is a
rationally-designed cyclodextrin which does not undergo
significant tubular reabsorption, thus it was formulated to
prevent injury to renal tubular cells. Animal studies with
SBECD have not shown discrete changes in renal morph-
ology at doses used clinically [11]; moreover, SBECD is
not nephrotoxic in these models when given at dose
equivalents of naturally occurring cyclodextrins that are
associated with nephrotoxicity and/or hepatotoxicity.
However, at the time of FDA approval, a lack of informa-
tion regarding the safety of SBECD in patients with
impaired renal function led to warnings against the use of
SBECD in patients with Clcr < 50 mL/min for products
including intravenous voriconazole [12]. This study is
important to clinicians because it provides evidence that
SBECD-containing medications can be used to treat
patients with serious fungal infections including those
with impaired renal function without increased risk of
nephrotoxicity.
Our main finding that treatment of a serious fungal
infection for patients with impaired renal function with
SBECD-containing voriconazole is not associated with
worse renal outcomes than treatment with a non-
SBECD containing alternative antifungal is consistent
with recent smaller studies. A retrospective analysis of
the Candida Phase 3 trial database for nephrotoxic
effects of intravenous voriconazole containing SBECD
did not detect renal toxicity from voriconazole in con-
trast to the renal dysfunction associated with amphoter-
icin B [10,15]. Despite accumulation of SBECD in the
plasma of patients with compromised renal function
[16-18], its lack of reabsorption in renal epithelial cells
appears to prevent deleterious effects on renal function
in this and other clinical reports [19-21].
Targeting high risk patients may have increased the
ability of our study of modest size to detect differences
among agents with regard to renal toxicity. The associ-
ation of fluconazole with worse renal function during
therapy is consistent with its labeling: “In some patients,
particularly those with serious underlying diseases such
as AIDS and cancer, changes in renal and hematological
function test results and hepatic abnormalities have
been observed during treatment with fluconazole and
comparative agents, but the clinical significance and
relationship to treatment is uncertain [22].” Our find-
ings do not identify fluconazole as a direct nephrotoxin,
rather they imply that the underlying disease state of
which fluconazole is treating influences renal function.
This is consistent with our identification of the organ-
ism as a significant predictor of renal outcome. The
association was driven by worse renal function among
those with systemic fungal infections, many of whom
were treated with fluconazole for sensitive isolates of
Candida albicans. It is important to note that all cases
of renal impairment were classified as mild-to-moderate
according to the RIFLE criteria [23]. We did not find
evidence for other possible mechanisms of renal toxicity
such as obstructive hydronephrosis [24-31] or microan-
giopathy such as that which occurs with hemolytic
uremic syndrome [32,33].
This study has important limitations that should be
taken into account when interpreting the data. It is a
nonrandomized observational study of clinical practice
at an academic medical center with policies that
mandate the involvement of infectious disease experts
for cases involving the administration of intravenous
antifungals for nearly all patients. This leads to differ-
ences among the groups that are due to non-random
factors that may be important. On the other hand, this
approach may be more informative about the effects in
clinical practice because cases are not excluded. We
attempted to review patient cases with compromised
renal function treated with amphotericin B but, despite
our large database, we could not find a sufficient num-
ber of patients meeting this criteria. Similarly, the num-
ber of patients with compromised renal function treated
with intravenous voriconazole is low and likely related
to labeling that raises concerns about renal toxicity in
this group.
Mortality was higher in the voriconazole group
compared with the other two groups, likely as a result of
the severity of the underlying fungal disease. A greater
percentage of patients in the voriconazole group was
infected with Aspergillus spp. A higher mortality rate is
expected in this group because infection with Aspergillus
spp. has been associated with higher mortality rates
compared to yeast infections. In addition, a greater
percentage of patients in the voriconazole group were
treated with voriconazole prophylactically as part of a
treatment plan for poor prognosis malignancies includ-
ing acute myelogenous leukemia (AML). Importantly,
differences among the indications for antifungal treat-
ment did not appear to alter the validity of the associ-
ation of the infecting organism that was isolated with
the development of renal dysfunction. Nonetheless,
there was a limited number of Candida and Aspergillus
isolates identified in this study such that associations
between the subspecies of yeast or mould with more
severe renal disease could not be definitive.
Another limitation of this study is the lack of dosing in-
formation or therapeutic drug monitoring. At the time of
data collection, there was no harmonization between phar-
macy and medical records. However, there are defined
guidelines for the dosing of the three IV antifungals estab-
lished by the Food and Drug Administration which were
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reviewed by a UMass clinical pharmacist. Antifungal agent
levels were not measured as part of this study and are not
recommended by current therapeutic guidelines. The
effects of SBECD on renal function that we observed do
not suggest that measuring drug levels to prevent renal tox-
icity would be justified.
Conclusions
A main finding of this study is that the administration of
SBECD in renally-compromised patients does not result
in renal damage that is attributable to its inclusion in
the formulation of voriconazole. The finding that the
infecting organism is a significant predictor of renal
outcomes in this high risk population suggests that the
efficacy of the antifungal agent should be the dominant
consideration when treating a serious fungal infection.
Further studies are warranted to help us better under-
stand the association between the underlying fungal
infection and acute kidney injury.
Methods
Patients/samples
We analyzed deidentified data from a large database of
hospitalized patients from the UMass Memorial
Healthcare System using the University of Massachusetts
Biorepository database. All adults with documented or
clinically suspected fungal infections that were treated
with an intravenous antifungal therapy, specifically,
voriconazole, fluconazole, or caspofungin, with baseline
estimated Clcr < 50 mL/min, and who were hospitalized
between 1/1/2007 and 12/31/2010 were identified. Those
eligible for analysis had been dosed for a minimum of
4 days of IV antifungal therapy and had serum creatinine
(Scr) levels while on therapy and at the end of IV antifun-
gal therapy (EOT; ± 3 days). Patients were excluded from
analyses if they had unstable renal function at baseline
(assessed as a 50% difference in Scr or estimated Clcr on
two measurements within 4 days prior to start of IV anti-
fungal therapy). Patients undergoing chronic hemodialysis,
hemofiltration, or other renal replacement therapies were
excluded from study. All concomitant medications which
could be considered nephrotoxic were evaluated in a
blinded fashion (by DRL) and subsequently tabulated by
treatment group (by VLW). The indication for treatment
with an antifungal agent was classified as for prophylaxis,
empiric treatment, or presumed/confirmed disease utiliz-
ing the EORTC guidelines [34].
Scr levels below 0.7 mg/dL were rounded up to
0.7 mg/dL per standard protocol [35,36] Clcr was
estimated by the Cockcroft-Gault equation:
Clcr ¼ 140 Ageð Þ  ABW  0:85 if Female½ 
72 Scr
Age is in years, ABW is actual body weight in kilo-
grams, and Scr is measured in milligrams per deciliter
[37-39]. Given the controversy in the literature regard-
ing the best estimator of renal function [36], we also
evaluated renal function by the Modification of Diet in
Real Disease (MDRD) study equation [40]:
Clcr ¼ eGFR
¼ 186 Scrð Þ1:154  AGEð Þ0:203
 0:742 if Femaleð Þ  1:212 if Blackð Þ
This study was performed with the prior approval of the
University of Massachusetts Human Subjects Committee
under a waiver of the requirement for informed consent.
Statistical analysis
Changes in Scr levels and Clcr were evaluated during IV
antifungal therapy. The highest Scr and lowest Clcr while
on therapy and at EOT among the groups were compared
with baseline Scr and Clcr, respectively, by F-test. We
compared dichotomous variables with the Fisher’s exact
test, and other categorical variables with the χ2 test.
Continuous variables were compared using the F test or
Wilcoxon rank-sum test and differences among groups
with the log-rank test. Distributions of length of treatment
were skewed, so these data are shown as median (IQR),
and other data are shown as mean (SD). We assessed
development of renal dysfunction with RIFLE scores [23]
by linear test of trend. 2-sided p values < 0.05 were consid-
ered statistically significant.
Stepwise logistic regression was conducted with a
p-value to enter and stay in the model set for p≤0.20.
The dependent variable in the model was the presence
of AKI. Prespecified potential independent variables
included age, gender, body mass index, antifungal ther-
apy, infecting organism, presence or absence of SBECD,
site of infection, Clcr at baseline, presence or absence of
concomitant potentially nephrotoxic agents, and comor-
bidities. For all analyses except the regression model,
p < 0.05 was considered significant. Analyses were
conducted using SAS Software version 9.2 (Cary, North
Carolina, USA).
Abbreviations
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